{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:29:01Z","timestamp":1794018541113,"version":"4.8.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004897","name":"European Organisation for Research and Treatment of Cancer","doi-asserted-by":"publisher","award":["006-2017"],"award-info":[{"award-number":["006-2017"]}],"id":[{"id":"10.13039\/501100004897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004897","name":"European Organisation for Research and Treatment of Cancer","doi-asserted-by":"publisher","award":["006-2017"],"award-info":[{"award-number":["006-2017"]}],"id":[{"id":"10.13039\/501100004897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004897","name":"European Organisation for Research and Treatment of Cancer","doi-asserted-by":"publisher","award":["006-2017"],"award-info":[{"award-number":["006-2017"]}],"id":[{"id":"10.13039\/501100004897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004897","name":"European Organisation for Research and Treatment of Cancer","doi-asserted-by":"publisher","award":["006-2017"],"award-info":[{"award-number":["006-2017"]}],"id":[{"id":"10.13039\/501100004897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The European Organisation for Research and Treatment of Cancer Quality of Life Multiple Myeloma Questionnaire (EORTC QLQ-MY20) was developed in 1996 to assess health-related quality of life (HRQoL) in patients with multiple myeloma. Since its development new therapies have prolonged survival in patients with myeloma and new combination agents are likely to impact HRQoL outcomes and its measurement.<\/jats:p><jats:p>The aim of this review was to explore the use of the QLQ-MY20 and reported methodological issues.<\/jats:p><jats:p>An electronic database search was conducted (1996-June 2020) to identify clinical studies\/research that used the QLQ-MY20 or assessed its psychometric properties. Data were extracted from full-text publications\/conference abstracts and checked by a second rater.<\/jats:p><jats:p>The search returned 65 clinical and 9 psychometric validation studies. The QLQ-MY20 was used in interventional (<jats:italic>n<\/jats:italic>\u2009=\u200921, 32%) and observational (<jats:italic>n<\/jats:italic>\u2009=\u200944, 68%) studies and the publication of QLQ-MY20 data in clinical trials increased over time. Clinical studies commonly included relapsed patients with myeloma patients (<jats:italic>n<\/jats:italic>\u2009=\u200915, 68%) and assessed a range of combinations therapies.<\/jats:p><jats:p>QLQ-MY20 subscales (disease symptoms [DS], side effects of treatment [SE], future perspectives [FP], body image [BI]) were defined as secondary (<jats:italic>n<\/jats:italic>\u2009=\u200912, 55%) or exploratory (<jats:italic>n<\/jats:italic>\u2009=\u20097, 32%) trial endpoints, particularly DS (<jats:italic>n<\/jats:italic>\u2009=\u200916, 72%) and SE (<jats:italic>n<\/jats:italic>\u2009=\u200916, 72%). Validation articles demonstrated that all domains performed well regarding internal consistency reliability (&gt;0.7), test-reset reliability (intraclass correlation coefficient\u2009&gt;\u2009=0.85), internal and external convergent and discriminant validity. Four articles reported a high percentage of ceiling effects in the BI subscale; all other subscales performed well regarding floor and ceiling effects.<\/jats:p><jats:p>The EORTC QLQ-MY20 remains a widely used and psychometrically robust instrument. While no specific problems were identified from the published literature, qualitative interviews are ongoing to ensure new concepts and side effects are included that may arise from patients receiving novel treatments or from longer survival with multiple lines of treatment.<\/jats:p>","DOI":"10.1038\/s41408-023-00815-9","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T04:03:26Z","timestamp":1684209806000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development"],"prefix":"10.1038","volume":"13","author":[{"given":"K.","family":"Forde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2595-708X","authenticated-orcid":false,"given":"K.","family":"Cocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. R.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1545-3137","authenticated-orcid":false,"given":"C.","family":"Kyriakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"EORTC Quality of Life Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"key":"815_CR1","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/ejh.12790","volume":"97","author":"C Ramsenthaler","year":"2016","unstructured":"Ramsenthaler C, Kane P, Gao W, Siegert RJ, Edmonds PM, Schey SA, et al. Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta\u2010analysis. Eur J Haematol. 2016;97:416\u201329.","journal-title":"Eur J Haematol"},{"key":"815_CR2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","volume":"36","author":"M Binder","year":"2021","unstructured":"Binder M, Nandakumar B, Rajkumar SV, Kapoor P, Buadi FK, Dingli D, et al. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia. 2021;36:801\u20138.","journal-title":"Leukemia"},{"key":"815_CR3","first-page":"2516","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. J Am Soc Hematol. 2008;111:2516\u201320.","journal-title":"J Am Soc Hematol"},{"key":"815_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/COC.0b013e3182a4676b","volume":"38","author":"J El-Amm","year":"2015","unstructured":"El-Amm J, Tabbara IA. Emerging therapies in multiple myeloma. Am J Clin Oncol. 2015;38:315\u201321.","journal-title":"Am J Clin Oncol"},{"key":"815_CR5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos M-V, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:309\u201322.","journal-title":"Ann Oncol"},{"key":"815_CR6","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/j.clml.2020.10.002","volume":"21","author":"M Engelhardt","year":"2021","unstructured":"Engelhardt M, Ihorst G, Singh M, Rieth A, Saba G, Pellan M, et al. Real-world evaluation of health-related quality of life in patients with multiple myeloma from Germany. Clin Lymphoma Myeloma Leuk. 2021;21:e160\u2013e75.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"815_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-016-2410-2","volume":"16","author":"C Ramsenthaler","year":"2016","unstructured":"Ramsenthaler C, Osborne TR, Gao W, Siegert RJ, Edmonds PM, Schey SA, et al. The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study. BMC cancer. 2016;16:1\u201316.","journal-title":"BMC cancer"},{"key":"815_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00543-y","volume":"11","author":"LL Fernandes","year":"2021","unstructured":"Fernandes LL, Zhou J, Kanapuru B, Horodniceanu E, Gwise T, Kluetz PG, et al. Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement. Blood cancer J. 2021;11:1\u20136.","journal-title":"Blood cancer J"},{"key":"815_CR9","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1046\/j.1365-2141.1999.01206.x","volume":"104","author":"M Stead","year":"1999","unstructured":"Stead M, Brown J, Velikova G, Kaasa S, WISL\u00d8FF F, CHILD J, et al. Development of an EORTC questionnaire module to be used in health\u2010related quality\u2010of\u2010life assessment for patients with multiple myeloma. Br J Haematol. 1999;104:605\u201311.","journal-title":"Br J Haematol"},{"key":"815_CR10","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","volume":"43","author":"K Cocks","year":"2007","unstructured":"Cocks K, Cohen D, Wisloff F, Sezer O, Lee S, Hippe E, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer. 2007;43:1670\u20138.","journal-title":"Eur J Cancer"},{"key":"815_CR11","unstructured":"European Organisation for Research and Treatment of Cancer. Multiple Myeloma - EORTC - Quality of Life: EORTC Quality of Life 2020 [cited 2022. Available from: https:\/\/qol.eortc.org\/questionnaire\/qlq-my20\/."},{"key":"815_CR12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/ejh.12012","volume":"89","author":"TR Osborne","year":"2012","unstructured":"Osborne TR, Ramsenthaler C, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ. What issues matter most to people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools. Eur J Haematol. 2012;89:437\u201357.","journal-title":"Eur J Haematol"},{"key":"815_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-020-0273-x","volume":"10","author":"MA Dimopoulos","year":"2020","unstructured":"Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, Blad\u00e9 J, et al. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood cancer J. 2020;10:1\u201319.","journal-title":"Blood cancer J"},{"key":"815_CR14","unstructured":"Wheelwright S, Bjordal K, Bottomley A, Gilbert A, Martinelli F, Pe M, et al. EORTC Quality of Life Group Guidelines for Developing Questionnaire Modules. Fifth ed 2021."},{"key":"815_CR15","unstructured":"Faria S, Ferreira G, Pereira M, Silva I, Pinheiro M, Bacalhau R, et al., editors. Unmet needs and quality of life in portuguese elderly myeloma patients. PSYCHO-ONCOLOGY; 2017: WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA."},{"key":"815_CR16","doi-asserted-by":"crossref","unstructured":"Pezzullo L, Serio B, Fontana R, Ferrara I, Sessa M, Giudice V, et al. Induction Therapy With Continuous Alternate-Day Low Dose Lenalidomide Combined With Low-Dose Prednisone In Octogenarian Multiple Myeloma Patients. American Society of Hematology Washington, DC; 2013.","DOI":"10.1182\/blood.V122.21.5394.5394"},{"key":"815_CR17","doi-asserted-by":"publisher","first-page":"842867","DOI":"10.1100\/2012\/842867","volume":"2012","author":"N Kontodimopoulos","year":"2012","unstructured":"Kontodimopoulos N, Samartzis A, Papadopoulos AA, Niakas D. Reliability and validity of the Greek QLQ-C30 and QLQ-MY20 for measuring quality of life in patients with multiple myeloma. Sci World J. 2012;2012:842867.","journal-title":"Sci World J"},{"key":"815_CR18","first-page":"741","volume":"13","author":"EA Calhoun","year":"2003","unstructured":"Calhoun EA, Welshman E, Chang CH, Lurain J, Fishman D, Hunt T, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group\u2014Neurotoxicity (Fact\/GOG\u2010Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer. 2003;13:741\u20138.","journal-title":"Int J Gynecol Cancer"},{"key":"815_CR19","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual life Res. 2011;20:1727\u201336.","journal-title":"Qual life Res"},{"key":"815_CR20","unstructured":"Hospital Anxiety and Depression Scale (HADS) [Available from: https:\/\/www.svri.org\/sites\/default\/files\/attachments\/2016-01-13\/HADS.pdf."},{"key":"815_CR21","unstructured":"Functional Assessment of Chronic Illness Therapy \u2013 Fatigue Scale [Available from: https:\/\/www.facit.org\/measures\/FACIT-Fatigue."},{"key":"815_CR22","unstructured":"Pittsburgh Sleep Quality Index (PSQI) [Available from: https:\/\/www.goodmedicine.org.uk\/files\/assessment,pittsburghpsqi.pdf."},{"key":"815_CR23","unstructured":"Karnofsky Performance Status Scale [Available from: https:\/\/www.mdcalc.com\/calc\/3168\/karnofsky-performance-status-scale."},{"key":"815_CR24","doi-asserted-by":"crossref","unstructured":"Nielsen LK, Klausen T, Kristensen IB, Abildgaard N, Gregersen H Clarithromycin added to the VCD regimen causes reduced health-related quality of life in multiple myeloma patients. 2018.","DOI":"10.1111\/ejh.13175"},{"key":"815_CR25","first-page":"255","volume":"17","author":"A Ahmadzadeh","year":"2016","unstructured":"Ahmadzadeh A, Yekaninejad MS, Saffari M, Pakpour AH, Aaronson NK. Reliability and validity of an Iranian version of the European Organisation for Research and Treatment of Cancer quality of life questionnaire for patients with multiple myeloma: The EORTC QLQ-MY20. J Cancer Prev. 2016;17:255\u20139.","journal-title":"J Cancer Prev"},{"key":"815_CR26","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s00277-014-2290-y","volume":"94","author":"JR Espinoza-Zamora","year":"2015","unstructured":"Espinoza-Zamora JR, Portilla-Espinosa CM, Labardini-M\u00e9ndez JR, Cervera E, Niesvisky R, O\u00f1ate-Oca\u00f1a LF. Quality of life in multiple myeloma: clinical validation of the Mexican-Spanish version of the QLQ-MY20 instrument. Ann Hematol. 2015;94:1017\u201324.","journal-title":"Ann Hematol"},{"key":"815_CR27","doi-asserted-by":"publisher","first-page":"e13128","DOI":"10.1111\/ecc.13128","volume":"28","author":"M Gra\u00e7a Pereira","year":"2019","unstructured":"Gra\u00e7a Pereira M, Ferreira G, Pereira M, Faria S, Bacalhau R, Monteiro S, et al. Validation of the Quality of Life Multiple Myeloma Module Questionnaire (QLQ\u2010MY20) in Portuguese myeloma patients. Eur J Cancer Care. 2019;28:e13128.","journal-title":"Eur J Cancer Care"},{"key":"815_CR28","doi-asserted-by":"crossref","unstructured":"Leleu X, Petrucci MT, Welslau M, Broek IV, Murphy PT, Bottomley A, et al. Psychometric performance of the EORTC Quality-of-Life Core questionnaire (QLQ-C30) and QLQ-Multiple Myeloma (QLQ-MY20) in relapsed\/refractory multiple myeloma (RRMM). American Society of Hematology Washington, DC; 2013.","DOI":"10.1182\/blood.V122.21.1721.1721"},{"key":"815_CR29","unstructured":"Murphy P, Leleu X, Kyriakou C, Vande Broek I, Welslau M, Bacon P, et al., editors. Psychometric evaluation of EORTC Quality-of-Life Core (QLQ-C30) and QLQ-multiple myeloma (QLQ-MY20) questionnaires to assess physician perception in patients with relapsed\/refractory multiple myeloma. Haematologica; 2014: Ferrata Storti Foundation via Giuseppe Belli 4, 27100 Pavia, Italy."},{"key":"815_CR30","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1016\/j.clml.2015.07.442","volume":"15","author":"O Sevindik","year":"2015","unstructured":"Sevindik O, Alacacioglu I, Payzin K, Yavuzsen T, Ozdemirkiran F, Yildirim T, et al. Quality of Life in Multiple Myeloma: Validation of the Turkish Version of the Qlq-My20 Instrument. Clin Lymphoma, Myeloma Leuk. 2015;15:e202.","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"key":"815_CR31","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/ejh.13316","volume":"103","author":"K Sully","year":"2019","unstructured":"Sully K, Trigg A, Bonner N, Moreno\u2010Koehler A, Trennery C, Shah N, et al. Estimation of minimally important differences and responder definitions for EORTC QLQ\u2010MY20 scores in multiple myeloma patients. Eur J Haematol. 2019;103:500\u20139.","journal-title":"Eur J Haematol"},{"key":"815_CR32","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1200\/JCO.2005.04.0824","volume":"24","author":"D Dubois","year":"2006","unstructured":"Dubois D, Dhawan R, van de Velde H, Esseltine D, Gupta S, Viala M, et al. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. J Clin Oncol. 2006;24:976\u201382.","journal-title":"J Clin Oncol"},{"key":"815_CR33","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s00277-011-1224-1","volume":"90","author":"SG Verelst","year":"2011","unstructured":"Verelst SG, Termorshuizen F, Uyl-de Groot C, Schaafsma M, Ammerlaan A, Wittebol S, et al. Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. Ann Hematol. 2011;90:1427\u201339.","journal-title":"Ann Hematol"},{"key":"815_CR34","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3324\/haematol.2012.074534","volume":"98","author":"MA Dimopoulos","year":"2013","unstructured":"Dimopoulos MA, Delforge M, H\u00e1jek R, Kropff M, Petrucci MT, Lewis P, et al. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. haematologica. 2013;98:784.","journal-title":"haematologica."},{"key":"815_CR35","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.3109\/10428194.2012.662643","volume":"53","author":"A Alegre","year":"2012","unstructured":"Alegre A, Oriol-Rocafiguera A, Garcia-Larana J, Mateos M-V, Sureda A, Martinez-Chamorro C, et al. Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience. Leuk lymphoma. 2012;53:1714\u201321.","journal-title":"Leuk lymphoma"},{"key":"815_CR36","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3324\/haematol.2014.120121","volume":"100","author":"M Delforge","year":"2015","unstructured":"Delforge M, Minuk L, Eisenmann J-C, Arnulf B, Canepa L, Fragasso A, et al. Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. haematologica. 2015;100:826.","journal-title":"haematologica."},{"key":"815_CR37","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.clml.2015.05.007","volume":"15","author":"K Weisel","year":"2015","unstructured":"Weisel K, Dimopoulos M, Song KW, Moreau P, Palumbo A, Belch A, et al. Pomalidomide and low-dose dexamethasone improves health-related quality of life and prolongs time to worsening in relapsed\/refractory patients with multiple myeloma enrolled in the MM-003 randomized phase III trial. Clin Lymphoma Myeloma Leuk. 2015;15:519\u201330.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"815_CR38","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1200\/JCO.2016.66.9648","volume":"34","author":"AK Stewart","year":"2016","unstructured":"Stewart AK, Dimopoulos MA, Masszi T, \u0160pi\u010dka I, Oriol A, H\u00e1jek R, et al. Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. J Clin Oncol. 2016;34:3921.","journal-title":"J Clin Oncol"},{"key":"815_CR39","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/ajh.25134","volume":"93","author":"X Leleu","year":"2018","unstructured":"Leleu X, Masszi T, Bahlis NJ, Viterbo L, Baker B, Gimsing P, et al. Patient\u2010reported health\u2010related quality of life from the phase III TOURMALINE\u2010MM1 study of ixazomib\u2010lenalidomide\u2010dexamethasone versus placebo\u2010lenalidomide\u2010dexamethasone in relapsed\/refractory multiple myeloma. Am J Hematol. 2018;93:985\u201393.","journal-title":"Am J Hematol"},{"key":"815_CR40","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjh.15248","volume":"181","author":"PG Richardson","year":"2018","unstructured":"Richardson PG, Schlossman RL, Roy AN, Panneerselvam A, Acharyya S, Sopala M, et al. Patient\u2010reported outcomes of multiple myeloma patients treated with panobinostat after\u2265 2 lines of therapy based on the international phase 3, randomized, double\u2010blind, placebo\u2010controlled PANORAMA\u20101 trial. Br J Haematol. 2018;181:628\u201336.","journal-title":"Br J Haematol"},{"key":"815_CR41","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/bjh.15459","volume":"182","author":"KL Royle","year":"2018","unstructured":"Royle KL, Gregory WM, Cairns DA, Bell SE, Cook G, Owen RG, et al. Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study. Br J Haematol. 2018;182:816\u201329.","journal-title":"Br J Haematol"},{"key":"815_CR42","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1007\/s00277-018-3469-4","volume":"97","author":"D Cella","year":"2018","unstructured":"Cella D, McKendrick J, Kudlac A, Palumbo A, Oukessou A, Vij R, et al. Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study. Ann Hematol. 2018;97:2455\u201363.","journal-title":"Ann Hematol"},{"key":"815_CR43","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1200\/JCO.18.01006","volume":"37","author":"SH Ahmedzai","year":"2019","unstructured":"Ahmedzai SH, Snowden JA, Ashcroft AJ, Cairns DA, Williams C, Hockaday A, et al. Patient-reported outcome results from the open-label, randomized phase III myeloma X trial evaluating salvage autologous stem-cell transplantation in relapsed multiple myeloma. J Clin Oncol. 2019;37:1617.","journal-title":"J Clin Oncol"},{"key":"815_CR44","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1038\/s41375-019-0480-2","volume":"33","author":"P Moreau","year":"2019","unstructured":"Moreau P, Kumar S, Boccia R, Iida S, Goldschmidt H, Cocks K, et al. Convenience, satisfaction, health-related quality of life of once-weekly 70 mg\/m2 vs. twice-weekly 27 mg\/m2 carfilzomib (randomized ARROW study). Leukemia. 2019;33:2934\u201346.","journal-title":"Leukemia."},{"key":"815_CR45","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.3324\/haematol.2019.222299","volume":"105","author":"LK Nielsen","year":"2020","unstructured":"Nielsen LK, Stege C, Lissenberg-Witte B, Van Der Holt B, Mellqvist U-H, Salomo M, et al. Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. haematologica. 2020;105:1650.","journal-title":"haematologica."},{"key":"815_CR46","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1182\/blood.V118.21.811.811","volume":"118","author":"MA Dimopoulos","year":"2011","unstructured":"Dimopoulos MA, Jagannath S, Yoon S-S, Siegel DS, Lonial S, Hajek R, et al. Vantage 088: vorinostat in combination with bortezomib in patients with relapsed\/refractory multiple myeloma: results of a global, randomized phase 3 trial. Blood. 2011;118:811.","journal-title":"Blood."},{"key":"815_CR47","first-page":"S138","volume":"96","author":"N Ryman","year":"2011","unstructured":"Ryman N, Hammond L, Hall R, McCarthy H. Interim analysis of a study to investigate safety, quality of life (QOL), patient satisfaction & preference with domiciliary versus day ward administration of bortezomib. Haematologica. 2011;96:S138.","journal-title":"Haematologica."},{"key":"815_CR48","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1182\/blood.V128.22.3309.3309","volume":"128","author":"H Ludwig","year":"2016","unstructured":"Ludwig H, Moreau P, Dimopoulos MA, Mateos M-V, Kaiser MF, Feng S, et al. Health related quality of life results from the open-label, randomized, phase III endeavor trial evaluating carfilzomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood. 2016;128:3309.","journal-title":"Blood."},{"key":"815_CR49","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","volume":"130","author":"H Ludwig","year":"2017","unstructured":"Ludwig H, P\u00f6nisch W, Egle A, Knop S, Schreder M, Lechner D, et al. Health-related quality of life in patients with relapsed\/refractory multiple myeloma during treatment with ixazomib-thalidomide-dexamethasone followed by ixazomib maintenance. Blood. 2017;130:1857.","journal-title":"Blood."},{"key":"815_CR50","first-page":"5407","volume":"130","author":"RM Rifkin","year":"2017","unstructured":"Rifkin RM, Boccia RV, Kambhampati S, Richter JR, Usmani SZ, Aiello J, et al. Tourmaline US-MM6, an open-label, single-arm, multicenter study evaluating the effectiveness and safety of ixazomib in combination with lenalidomide and dexamethasone (IRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM) switching from a bortezomib-based triplet induction regimen. Blood. 2017;130:5407.","journal-title":"Blood."},{"key":"815_CR51","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1007\/s11136-017-1706-2","volume":"27","author":"HR Eshoj","year":"2018","unstructured":"Eshoj HR, Nielsen LK, Schjesvold F, Abildgaard N, Nahi H, Andersen NF, et al. Health-related quality of life in multiple myeloma patients with first relapse treated with Carfilzomib-based re-induction and salvage autologous stem cell transplantation: data from a Nordic phase II trial. Qual Life Res. 2018;27:S137.","journal-title":"Qual Life Res"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00815-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00815-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00815-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T17:11:49Z","timestamp":1684257109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00815-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["815"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00815-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,16]]},"assertion":[{"value":"7 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors Katie Forde, Kim Cocks, Jane R Wells and Isobel McMillan are or were at the time of the study employees of Adelphi Values Ltd. Adelphi Values Ltd was provided a grant from the EORTC Quality of Life Group to conduct the research described in this manuscript and to develop this manuscript. Adelphi Values Ltd provides consultancy for a variety of pharmaceutical companies. Dr Kyriakou had an unrestricted educational research grant from Celgene\/BMS.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"79"}}